We are live on
!
Find out more
CC
Checkpoint Capital Portfolio holdings
AUM
$279M
1-Year Est. Return
45.74%
This Fund
S&P 500
This Quarter
Est. Return
+4.4%
1 Year Est. Return
+45.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$196M
AUM Growth
-$5.09M
(-2.5%)
Cap. Flow
+$5.37M
Cap. Flow
% of AUM
2.73%
Top 10 Holdings %
Top 10 Hldgs %
91.55%
Holding
18
New
2
Increased
9
Reduced
4
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$10.6M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
+$9.53M |
| 3 |
Disc Medicine
IRON
|
+$9.22M |
| 4 |
TScan Therapeutics
TCRX
|
+$4.22M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
+$3.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cytokinetics
CYTK
|
+$23.2M |
| 2 |
Protagonist Therapeutics
PTGX
|
+$10.8M |
| 3 |
ATYR
aTyr Pharma
ATYR
|
+$3.95M |
| 4 |
Axsome Therapeutics
AXSM
|
+$3.21M |
| 5 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$1.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$54.1B
| $56.9M | 28.95% |
92,500
| – | – |
|
|
2
Rhythm Pharmaceuticals
RYTM
$7.96B
| $40.8M | 20.74% |
727,982
+64,601
| +10% | +$3.57M |
|
|
3
Phathom Pharmaceuticals
PHAT
$692M
| $18.5M | 9.4% |
2,274,157
+769,850
| +51% | +$9.53M |
|
|
4
Axsome Therapeutics
AXSM
$10.9B
| $14.8M | 7.53% |
174,769
-34,863
| -17% | -$3.21M |
|
|
5
Disc Medicine
IRON
$2.97B
| $11.7M | 5.97% |
185,000
+159,457
| +624% | +$9.22M |
|
|
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
| $10.6M | 5.37% |
1,004,790
-95,210
| -9% | -$1.16M |
|
|
7
Revolution Medicines
RVMD
$44B
| $9.19M | 4.68% |
+210,000
| New | +$10.6M |
|
8
Pliant Therapeutics
PLRX
$65M
| $7.05M | 3.59% |
535,494
+155,494
| +41% | +$2.12M |
|
|
9
TScan Therapeutics
TCRX
$52M
| $5.34M | 2.72% |
1,755,987
+930,646
| +113% | +$4.22M |
|
|
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
| $5.11M | 2.6% |
196,949
+14,523
| +8% | +$236K |
|
11
Trevi Therapeutics
TRVI
$2.64B
| $4.47M | 2.27% |
1,084,135
+834,135
| +334% | +$2.67M |
|
12
Stoke Therapeutics
STOK
$2.11B
| $3.37M | 1.71% |
305,387
+147,873
| +94% | +$1.82M |
|
|
SLNO
13
DELISTED
Soleno Therapeutics
SLNO
| $3.15M | 1.6% |
70,027
+12,044
| +21% | +$624K |
|
14
Kymera Therapeutics
KYMR
$8.94B
| $3.12M | 1.59% |
+77,535
| New | +$3.5M |
|
|
ATYR
15
aTyr Pharma
ATYR
$50.1M
| $1.57M | 0.8% |
432,561
-1,303,916
| -75% | -$3.95M |
|
|
16
Cytokinetics
CYTK
$10.4B
| $941K | 0.48% |
20,000
-446,813
| -96% | -$23.2M |
|
|
ALLK
17
DELISTED
Allakos
ALLK
| – | – |
-649,957
| Closed | -$425K |
|
|
18
Protagonist Therapeutics
PTGX
$9.44B
| – | – |
-240,000
| Closed | -$10.8M |
|
Similar funds
CB
SL
ACP
CCC
KWM
NCM
BWG
PBPIA
Checkpoint Capital's Q4 2024 Portfolio in Review
As of Q4 2024, Checkpoint Capital held 18 positions worth $196M, down 2.5% from $202M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Checkpoint Capital's Q4 2024 filing shows 2 new, 9 increased, 4 reduced and 2 closed positions. Its largest new stake was Revolution Medicines: 210,000 shares worth $9.19M. The largest sale was Cytokinetics, an estimated $23.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Checkpoint Capital's largest Q4 2024 buy was Revolution Medicines: 210,000 shares worth $9.19M.
- Checkpoint Capital added most to Phathom Pharmaceuticals in Q4 2024, an estimated $9.53M increase.
- Checkpoint Capital's biggest Q4 2024 reduction was Cytokinetics, cutting an estimated $23.2M.
- Checkpoint Capital fully exited Protagonist Therapeutics in Q4 2024, selling an estimated $10.8M.
- Checkpoint Capital's ten largest holdings make up 92% of its $196M portfolio in Q4 2024.
- Checkpoint Capital opened 2 new positions and closed 2 in Q4 2024.
- Checkpoint Capital's portfolio value fell 2.5% quarter-over-quarter to $196M.
Based on Checkpoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.